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Background
This study aimed to provide policy makers with important
information with regard to care of schizophrenia patients
in Thailand. Specifically, it aimed to (a) estimate the eco-
nomic burden of schizophrenia; (b) identify prioritized and
effective schizophrenia treatments; and c) explore patients’
and clinicians’ perspective of schizophrenia outcomes.
Materials and methods
This study was conducted at a national level, using the
government, patients and family’s perspectives. Both pri-
mary and secondary data were used. A cross-sectional sur-
vey was conducted in the year 2008. Data were also
obtained from both national and international literature
and databases. The concepts of Disability Adjusted Life
Year, Cost of Illness estimation and Generalized Cost-
Effectiveness Analysis were adopted to estimate burden of
schizophrenia and cost-effective interventions.
Results
The prevalence of schizophrenia at ages 15-59 in the Thai
population was 8.8 per 1,000 (95% CI: 7.2, 10.6) with a
male to female ratio of 1.1. The annual cost of schizophre-
nia was estimated to be THB 87,000 per person (95% CI:
83,000, 92,000) with indirect costs (73%) as the main cost
contributed. The most cost-effective treatment of schizo-
phrenia was generic risperidone as first line treatment
(dominant intervention), in a combination with family
interventions for all patients. Clozapine would be pre-
scribed only for severe patients. The results from the
survey also suggested a modest association between
patient-rated and clinician-rated outcomes. The patients
rated themselves using the EuroQol-5D+ instrument,
while the disease severity of each patient was rated by a
psychotic nurse using the Brief Psychiatric Rating Scale-
Expanded.
Conclusion
Schizophrenia is an expensive disorder in Thailand. By
providing more cost-effective interventions with a combi-
nation of generic risperidone, family interventions and
clozapine would achieve a win-win solution for both the
government and the patients/families. Policy makers and
clinicians need to consider real needs of patients in
future planning of schizophrenia management.
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